Exelixis: Financial Performance Improves Faster Than Market Expectations
Exelixis, Inc. has shown significant financial improvement, surpassing market expectations. The company's Q1 revenue increased by 10% year-over-year, primarily due to strong demand for its product CABOMETYX. With rising margins and robust free cash flow, Exelixis is considered undervalued, prompting a Buy rating with a target price of $57.
- ▪Exelixis stock rallied over 13% following the release of Q1 results.
- ▪The company's Q1 revenue growth was driven mainly by CABOMETYX demand.
- ▪Exelixis achieved an operating margin of 41.1% as costs decreased.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908314-exelixis-stock-financial-performance-improves-faster-than-market-expectations"},"author":{"@type":"Person","name":"Narek…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
